Effects of Anti-Calcitonin Gene-Related Peptide for Migraines: A Systematic Review with Meta-Analysis of Randomized Clinical Trials

CGRP monoclonal antibody for preventive treatment of chronic migraine: An update of meta-analysis

(2019) Lin Han et al.   Brain and Behavior

Efficacy and safety of galcanezumab for the prevention of episodic migraine: Results of the EVOLVE-2 Phase 3 randomized controlled clinical trial

(2018) Vladimir Skljarevski et al.   CEPHALALGIA

Efficacy and safety of erenumab (AMG334) in chronic migraine patients with prior preventive treatment failure: A subgroup analysis of a randomized, double-blind, placebo-controlled study

(2018) Messoud Ashina et al.   CEPHALALGIA

A phase 1 study to assess the pharmacokinetics, safety, and tolerability of fremanezumab doses (225 mg, 675 mg and 900 mg) in Japanese and Caucasian healthy subjects

(2018) Orit Cohen-Barak et al.   CEPHALALGIA

Sustained reductions in migraine days, moderate-to-severe headache days and days with acute medication use for HFEM and CM patients taking fremanezumab: Post-hoc analyses from phase 2 trials

(2018) Rashmi B Halker Singh et al.   CEPHALALGIA

Safety of galcanezumab in patients with episodic migraine: A randomized placebo-controlled dose-ranging Phase 2b study

(2018) Tina Marie Myers Oakes et al.   CEPHALALGIA

ARISE: A Phase 3 randomized trial of erenumab for episodic migraine

(2018) David W Dodick et al.   CEPHALALGIA

Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition

(2018)   CEPHALALGIA

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Erenumab on Exercise Time During a Treadmill Test in Patients With Stable Angina

(2018) Christophe Depre et al.   HEADACHE

A Review of Monoclonal Antibody Therapies and Other Preventative Treatments in Migraine

(2018) Uwe Reuter   HEADACHE

Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine

(2018) David W. Dodick et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Antibodies to watch in 2018

(2018) Hélène Kaplon et al.   mAbs

Evaluation of Galcanezumab for the Prevention of Episodic Migraine

(2018) Virginia L. Stauffer et al.   JAMA Neurology

Effect of Different Doses of Galcanezumab vs Placebo for Episodic Migraine Prevention

(2018) Vladimir Skljarevski et al.   JAMA Neurology

Measures of Functioning in Patients With Episodic Migraine: Findings From a Double-Blind, Randomized, Placebo-Controlled Phase 2b Trial With Galcanezumab

(2018) David W. Ayer et al.   HEADACHE

The efficacy and safety of calcitonin gene-related peptide monoclonal antibody for episodic migraine: a meta-analysis

(2018) Yuhan Zhu et al.   NEUROLOGICAL SCIENCES

Association of sperm source with miscarriage and take-home baby after ICSI in cryptozoospermia: a meta-analysis of testicular and ejaculated sperm

(2018) F.-Y. Ku et al.   Andrology

A phase 3, long-term, open-label safety study of Galcanezumab in patients with migraine

(2018) Angelo Camporeale et al.   BMC Neurology

The Effect of Beginning Treatment With Fremanezumab on Headache and Associated Symptoms in the Randomized Phase 2 Study of High Frequency Episodic Migraine: Post-Hoc Analyses on the First 3 Weeks of Treatment

(2018) Stephen D. Silberstein et al.   HEADACHE

Analysis of Initial Nonresponders to Galcanezumab in Patients With Episodic or Chronic Migraine: Results From the EVOLVE-1, EVOLVE-2, and REGAIN Randomized, Double-Blind, Placebo-Controlled Studies

(2018) Russell Nichols et al.   HEADACHE

100% Response Rate to Galcanezumab in Patients With Episodic Migraine: A Post Hoc Analysis of the Results From Phase 3, Randomized, Double-Blind, Placebo-Controlled EVOLVE-1 and EVOLVE-2 Studies

(2018) Noah Rosen et al.   HEADACHE

Early onset of efficacy with erenumab in patients with episodic and chronic migraine

(2018) Todd Schwedt et al.   JOURNAL OF HEADACHE AND PAIN

Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study

(2018) Uwe Reuter et al.   LANCET

Galcanezumab in chronic migraine

(2018) Holland C. Detke et al.   NEUROLOGY

Effects of three common lumbar interbody fusion procedures for degenerative disc disease: A network meta-analysis of prospective studies

(2018) En-Yuan Lin et al.   International Journal of Surgery

Do etoricoxib and indometacin have similar effects and safety for gouty arthritis? A meta-analysis of randomized controlled trials

(2018) Tzu-Min Lin et al.   Journal of Pain Research

Fremanezumab as Add-On Treatment for Patients Treated With Other Migraine Preventive Medicines

(2017) Joshua M. Cohen et al.   HEADACHE

The effect and safety of monoclonal antibodies to calcitonin gene-related peptide and its receptor on migraine: a systematic review and meta-analysis

(2017) Min Hou et al.   JOURNAL OF HEADACHE AND PAIN

Phase 3, randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of erenumab (amg 334) in migraine prevention: primary results of the strive trial

(2017) Peter J Goadsby et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

A phase 3, randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of erenumab in migraine prevention: primary results of the arise trial

(2017) David Dodick et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Global, regional, and national age-sex specific mortality for 264 causes of death, 1980–2016: a systematic analysis for the Global Burden of Disease Study 2016

(2017) Mohsen Naghavi et al.   LANCET

Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial

(2017) Stewart Tepper et al.   LANCET NEUROLOGY

Erenumab (AMG 334) in episodic migraine

(2017) Messoud Ashina et al.   NEUROLOGY

Fremanezumab for the Preventive Treatment of Chronic Migraine

(2017) Stephen D. Silberstein et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Controlled Trial of Erenumab for Episodic Migraine

(2017) Peter J. Goadsby et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pathophysiology of Migraine: A Disorder of Sensory Processing

(2017) Peter J. Goadsby et al.   PHYSIOLOGICAL REVIEWS

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the CGRP Binding Monoclonal Antibody LY2951742 (Galcanezumab) in Healthy Volunteers

(2017) David Monteith et al.   Frontiers in Pharmacology

Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomised, double-blind, placebo-controlled, phase 2 trial

(2016) Hong Sun et al.   LANCET NEUROLOGY

TEV-48125 for the preventive treatment of chronic migraine

(2016) Marcelo E. Bigal et al.   NEUROLOGY

The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist and Explanations

(2015) Brian Hutton et al.   ANNALS OF INTERNAL MEDICINE

Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of chronic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study

(2015) Marcelo E Bigal et al.   LANCET NEUROLOGY

Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a phase 2, randomised, double-blind, placebo-controlled study

(2014) David W Dodick et al.   LANCET NEUROLOGY

Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial

(2014) David W Dodick et al.   LANCET NEUROLOGY

Evidence-based guideline update: Pharmacologic treatment for episodic migraine prevention in adults: Table 1

(2012) S.D. Silberstein et al.   NEUROLOGY

CGRP and its receptors provide new insights into migraine pathophysiology

(2010) Tony W. Ho et al.   Nature Reviews Neurology